Thymosin beta 4: An emerging therapeutic candidate for kidney diseases.
This review synthesizes existing preclinical and emerging translational evidence on Thymosin β4 (Tβ4), a conserved 43-amino-acid peptide, and its N-terminal metabolite Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro), as potential therapeutic candidates in kidney disease. The authors map the intracellular and extracellular mechanisms of the Tβ4–Ac-SDKP axis, including its roles in actin sequestration, cytoprotection, anti-inflammatory signaling, and antifibrotic actions across both glomerular and tubular compartments. Evidence is evaluated across models of both acute and chronic kidney injury. The review acknowledges contradictory findings regarding fibrosis and proposes conceptual frameworks to explain bidirectional effects and model-dependent mechanisms. Translational considerations discussed include peptide pharmacokinetics, stability challenges, and drug delivery strategies. The authors note that key barriers to clinical translation remain, including the need for validation in additional clinically relevant models, resolution of peptide instability, and comprehensive safety profiling. As a narrative review, this paper does not generate new experimental data, and its conclusions are limited by the quality and heterogeneity of the underlying studies, most of which appear to be animal-based.
Why this grade: This is a narrative review synthesizing predominantly preclinical (animal and in vitro) evidence; no original human trial data are generated, so evidence grading defaults to the review category.
Over the past decades, the escalating global burden of kidney disease has underscored an urgent need for innovative therapeutic strategies. Thymosin β4 (Tβ4), a highly conserved 43-amino-acid peptide encoded by the X-linked TMSB4x gene, is the predominant β-thymosin in mammalian cells and a multifunctional regulator of cellular homeostasis. Once considered mainly an actin-sequestering molecule, Tβ4 and its N-terminal metabolite N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) now emerge as dynamic mediators of renal injury and repair. In this review, we synthesize current evidence on the Tβ4-Ac-SDKP axis. We map intra- and extracellular mechanisms and relevant signaling pathways, delineate cell-type and spatial expression across glomerular and tubular compartments, and critically evaluate its renoprotective efficacy-including cytoprotection, anti-inflammatory and antifibrotic actions-across models of acute and chronic kidney injury. To reconcile disparate findings, we propose conceptual frameworks that consider bidirectional effects on fibrosis and model-dependent mechanisms. Finally, translational opportunities are appraised with attention to pharmacokinetics, peptide stability and delivery strategies. Key challenges moving forward include validating efficacy in additional clinically relevant models, overcoming peptide instability and completing comprehensive safety assessments.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.